Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,941,092 papers from all fields of science
Search
Sign In
Create Free Account
MGCD 0103
Known as:
MG-0103
, MGCD-0103
, MGCD0103
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
mocetinostat
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Corrigendum: Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma
S. Coni
,
A. Mancuso
,
+16 authors
G. Canettieri
Scientific Reports
2017
Corpus ID: 7453315
Scientific Reports 7: Article number: 44079; published online: 09 March 2017; updated: 21 April 2017. In this Article, Monika…
Expand
2017
2017
Experimental Trial Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain
Wen-Jun Luo
,
Fan Yang
,
+8 authors
Jun Chen
2017
Corpus ID: 39006546
Methods: By IVF injection, a volume of 50 μl containing 30 μg/mL ozone-oxygen mixture or 50 μl air was carried out on male…
Expand
2016
2016
Abstracts of the 22nd Scientific Conference of the Society on Neuroimmune Pharmacology
Journal of Neuroimmune Pharmacology
2016
Corpus ID: 255276214
2014
2014
Abstract 4090: Inhibition of class I histone deacetylases promotes robust and durable enhancement of PDL1 expression in melanoma: Rationale for combination therapy
David M. Woods
,
Andressa L. Sodré
,
+6 authors
E. Sotomayor
2014
Corpus ID: 70356418
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Histone deacetylase inhibitors (HDACi) have shown…
Expand
2011
2011
Abstract 2625: MGCD0103, an oral isotype-selective HDAC inhibitor, has antitumor activity via the induction of the expression of Annexin A1 on AML1/ETO AMLin vitroandin vivo
Daisuke Nameki
,
N. Masuko
,
+4 authors
K. Matsuo
2011
Corpus ID: 71778544
MGCD0103 is a non-hydroxamate and an orally available isotype-selective HDAC inhibitor (HDACi) whose clinical activity has been…
Expand
2010
2010
Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinitiation and update of clinical efficacy and safety.
R. Martell
,
A. Younes
,
+7 authors
R. Jagt
2010
Corpus ID: 75608099
8086 Background: MGCD0103 is an orally available selective inhibitor of histone deacetylases (HDACs). Methods: Trial 008 is a…
Expand
2008
2008
Induction of the cancer-testis antigen MAGE-A3 in myeloma cell lines by 5’azacitidine and MGCD0103
A. Moreno
,
S. Szmania
,
Jumei Shi
,
B. Barlogie
,
G. Prentice
,
F. Rhee
2008
Corpus ID: 73967225
14008 Background: MAGE-A3 is an immunogenic cancer testis antigen that is frequently expressed in high-risk multiple myeloma. We…
Expand
2008
2008
Orphan drug designation granted for MGCD0103 in US
2008
Corpus ID: 195100032
2008
2008
MGCD0103, an oral isotype-selective HDAC inhibitor, significantly enhances the anti-tumor efficacy of Taxane via the unique modulation of angiogenesis gene expressions
H. Fujita
,
K. Murakami
,
Daisuke Nameki
,
Yositaka Ohsugi
,
Y. Yamasaki
,
K. Noguchi
2008
Corpus ID: 208482317
2446 Background: MGCD0103 is a novel orally available and isotype-selective HDAC inhibitor whose clinical activity has been…
Expand
2008
2008
Evaluation of the Pharmacodynamic Effects of MGCD 0103 from Preclinical Models to Human Using a Novel HDAC
C. Bonfils
,
A. Kalita
,
+6 authors
Zuomei Li
2008
Corpus ID: 11714139
Purpose: The pharmacodynamic properties of MGCD0103, an isotype-selective inhibitor of histone deacetylase (HDAC), were evaluated…
Expand